<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
	<title>Anti-Parkinsonics</title>
	<meta name='Generator' content='Zim 0.73.1'>
	<style type='text/css'>
		a          { text-decoration: none      }
		a:hover    { text-decoration: underline }
		a:active   { text-decoration: underline }
		strike     { color: grey                }
		u          { text-decoration: none;
					 background-color: yellow   }
		tt         { color: #2e3436;            }
		pre        { color: #2e3436;
					 margin-left: 20px          }
		h1         { text-decoration: underline;
					 color: #4e9a06; margin-bottom: 0 }
		h2         { color: #4e9a06; margin-bottom: 0 }
		h3         { color: #4e9a06; margin-bottom: 0 }
		h4         { color: #4e9a06; margin-bottom: 0 }
		h5         { color: #4e9a06; margin-bottom: 0 }
		p          { margin-top: 0              }
		span.zim-tag {
			color: #ce5c00;
		}
		div.zim-object {
			border-style:solid;
			border-width:1px;
		}
		.checked-box {list-style-image: url(data:image/png;base64,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)}
		.xchecked-box {list-style-image: url(data:image/png;base64,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)}
		.unchecked-box {list-style-image: url(data:image/png;base64,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)}
		.migrated-box {list-style-image: url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABgAAAAYCAYAAADgdz34AAAABGdBTUEAALGPC/xhBQAAAAZiS0dEAP8A/wD/oL2nkwAAAAlwSFlzAAANOgAADMQBiN+4gQAAAAd0SU1FB+AKHREFA8vJSnkAAAAZdEVYdENvbW1lbnQAQ3JlYXRlZCB3aXRoIEdJTVBXgQ4XAAAC1klEQVRIx+2VT0hUURTGf/e958w4Tc3TYowMw1GyEgwr1MqsFmbZIrIWQZsWJUjbdoHQpl3Qps0swnCRECQFYkR/TC1iKkqmfzAKTo2Vf8hoRsfR995tkRMT87RRWkUHHhy495zvnvvu933wP/75EKkkEAjIYDCIaZpIKRFCZN0kfX9xcTGtra2/irVUEolECIfDlJeXo+s6hmFkDaCqKoZhEAqFSCaTv60pqcSyLAoLC/F4PEtqDmCaJkIIKisrMybX0sdUVRWA5ubmPzdNjjI1cpXkZC/O1fV03PXgdDqRUtpPIITAsqxsDz0Z/3CZQv8uqo4N4C8/Tp2/DdM0MiZQlvk41OTkI/LW1SGtCVb5drD3eCc71wcA+VcAHA5vDd8+3UGakxiJV7i9pdQevU5T1R35pJ3MV5QW1pf+0kWBheJ2SWua8EQXZXsu4fVVYEz1sEKvof5EuxjoPvzpcRvrdp9C2gGMx6cpOHBmbImMesds7BZubwMVDTfXDnQ3vQfK7AC8wLfExMX5whyQc3q2OEnjGm5vE76SQxsfBLr77a7CNf+n0r/l6sSMtsBSnurckiIILCobAtVZhpF4gZF4jubaymj4Ch/fd380LE7bAnjc0NPxk2yqpmEuwGxF0ag+0k5uTpzZeBeaazvj0We8fXojainsb2xh2BZgbe0gSIllzSIUh63wfQ6dZ/O2fbjcKlOj58jJ3cVENESw5yErc9nf2MLQ4jwQAkV1Lqiq37/cZ9WaahJjF9AcmxiPDhLs7ePe23oOnmUwg2hSShQle96tKDjA2HAniusgo9FxnvY9Jxw7RWzGYy92QghM00x5g53qp9sHmtB58/o2umOI2NwGolMnMYUHIb7aAyiKwsjICLqu2/qBEIKUUAohMaSHSLyBSMoPTINQ6CX5+fn2AEVFRZSUlBCPx4nFYhl3L4RESjF/GEgX3pSj+Xw+/H7/b3U/AEOZFnp7O5+5AAAAAElFTkSuQmCC)}
		ul {list-style-image: none}
		/* ul rule needed to reset style for sub-bullets */
	</style>
</head>
<body>

<!-- Header -->
<div class='header'>
	[ <a href='./Pharmacognosy.html'>Prev</a> ]

	[ <span class='insen'>Index</span> ]

	[ <a href='..\15.html'>Next</a> ]
</div>

<hr />

<!-- Wiki content -->

<div class='pages'>
	<div class='heading'>
	<h1>Anti-Parkinsonics <a name='14:Pharmacology'></a></h1>
	</div>

	<div class='content'>
	
<p>
→ Tremor<br>
<ul style='padding-left: 30pt'>
<li>rythmic oscillatory movement around a joint and is best characterized by its relation to activity.</li>
</ul>
→ Tremor at rest:<br>
<ul style='padding-left: 30pt'>
<li>Parkinsonism [rigidity/impairment of voluntary activity]</li>
</ul>
→ may occur during maintence of :<br>
<ul style='padding-left: 30pt'>
<li>sustained posture [ postural tremor ]</li>
<li>during movemnt [ intention tremor ] — [lession of the brainstream/cerebellum]</li>
</ul>
→ Chorea consist of <br>
<ul style='padding-left: 30pt'>
<li>irregular , unpredictable , involuntary muscle jerks that occur in different parts of the  body → impair voluntary activity </li>
<li>proximal muscsles of the limb mostly affected</li>
</ul>
→ Athetosis :<br>
<ul style='padding-left: 30pt'>
<li>slow and wirthing movement</li>
</ul>
→ Dystonia :<br>
<ul style='padding-left: 30pt'>
<li>sustained abnormal postures (dystonia) — [perinatal brain damage] — [ from acute complication of certain drugs,diverse neurologic disorder,inhereted phenomenon ]</li>
</ul>
</p>

<h1>1.Parkinsonism</h1>

<p>
→ characterized by a combination of :<br>
<ul style='padding-left: 30pt'>
<li>rigidity   </li>
<li>bradykinesia</li>
<li>tremor</li>
<li>postural instability </li>
</ul>
→ usually idiopathic reasons (Parkison disease)<br>
→ non-motor symptoms<br>
<ul style='padding-left: 30pt'>
<li>affective disorders</li>
<li>personality changes</li>
<li>abnormalities in autonomic functions (sphincter,sexual functions,sweating)</li>
<li>sleep disorders</li>
<li>sensory complains or pains</li>
</ul>
→ very progressive leading to increasing disability unless effective treatment
</p>

<h1>1.1.pathogenesis</h1>

<p>
→ related in combination of :<br>
<ul style='padding-left: 30pt'>
<li>impaired degradation of proteins</li>
<li>intracellular protein accumulation</li>
<li>aggregation</li>
<li>oxidative stress</li>
<li>mitochondrial damage</li>
<li>inflammatory cascades</li>
<li>apoptosis</li>
<li>genetic factors are important (under age of 50) </li>
</ul>
→ mutation of the α-synuclein gene at 4q21 associated with Parkinson<br>
<ul style='padding-left: 30pt'>
<li>which is now recognized as synucleinopathy</li>
</ul>
→ (Stage 1 of Baark) — olfacotry nucleus and lower brainsteam<br>
<div style='padding-left: 30pt'>
 (Stage 2 ) — higher brainsteam<br>
 (Stage 3) — substania nigra<br>
 (Stage 4) — mesocortex and thalamus<br>
 (Stage 5) — entire neocortex
</div>
<ul>
<li>motor features develop at stage 3</li>
</ul>
</p>

<p>
→ normally high concentration of dopamine in the basal ganglia of the brain<br>
<ul style='padding-left: 30pt'>
<li>is reduced in parkinsonism</li>
</ul>
→ pharmacological :<br>
<ul>
<li>restore dopaminergic activity with levodopa and dopamine agonist allevite many of the motor features of the disorder.</li>
</ul>
</p>

<p>
→ normally inhibition of GABAergic cells in the corpus striatium is LOST.<br>
→ drugs induced parkinson :<br>
<ul style='padding-left: 30pt'>
<li>dopamine receptor agonist (antipsycotics)</li>
<li>1-methyl-4-phenyl-1-,2,3,6-tetrahydropyridine [MPTP]</li>
<li>various other neurotranmitters such as norepinephrine has uncertain clinical relevance.</li>
<li><img src="./Pharmacology/pasted_image.png"></li>
</ul>
</p>
<h1>2.LEVODOPA</h1>

<br>

<p>
→ does not cross the blood-brain barrier<br>
<ul style='padding-left: 30pt'>
<li>no effect if given into peripheral circulation</li>
</ul>
→ (-)-3-(3,4-dihydroxyphenyl)-L-alanine [<i>levodopa</i>]<br>
<ul style='padding-left: 30pt'>
<li>immediate meatbolic prescusor of dopamine</li>
<li>does enter brain → decarboxylated in <i>dopamine.</i></li>
</ul>
→Dopamine receptors<br>
<ul style='padding-left: 30pt'>
<li>D1 type → in the pars of compacta of the substania nigra</li>
</ul>
presynaptically: — on striatal axons comming from cortical neurons and from dopa cells in the substantia nigra<br>
<ul style='padding-left: 30pt'>
<li>D2 type →  on striatal neurons</li>
</ul>
presynaptically — on axons in the substantia nigra (basan ganglia)<br>
→ benifit of dopaminergic antipakrinsonism drug appear to depend mostly in the stimulation of D2 receptor.<br>
<ul style='padding-left: 30pt'>
<li>D3 type → of newer drugs</li>
</ul>
→ Dopamine agoinst or partial agonist "ergot derivatives"<br>
<ul style='padding-left: 30pt'>
<li><i>lergotrile &amp; bromocriptine</i></li>
</ul>
→ dopamine blockers that are selective on D2 induce parkinsonism.
</p>

<p>
→ Dopa is the amino acid prescursor of dopamine and norepinephrine<br>
<ul style='padding-left: 30pt'>
<li>Levodopa is the levorotary stereoismoer of dopa.</li>
</ul>
</p>

<p>
Chemistry Chapter 6 <a href="file:///C:/Users/nksse/OneDrive/Documents/MEGAsync/state%2Bthesis/StateExams/Pharmacognsoy/E-books/katzung-pharmacology.pdf" title="file:///C:/Users/nksse/OneDrive/Documents/MEGAsync/state+thesis/StateExams/Pharmacognsoy/E-books/katzung-pharmacology.pdf" class="file">file:///C:/Users/nksse/OneDrive/Documents/MEGAsync/state+thesis/StateExams/Pharmacognsoy/E-books/katzung-pharmacology.pdf</a>
</p>

<h1>2.1 pharmacokinetics:</h1>

<br>

<p>
→ rapidly absorbed from the small intenstine<br>
<ul style='padding-left: 30pt'>
<li>absortption depends on — rate of gastric acid emptying — pH of gastric content </li>
</ul>
→ ingestion of food delay the appearence of levodopa in the plasma<br>
→ plasma conc. peak : 1 &amp; 2 hours after an oral dose<br>
→ plasma half-life: 1-3 hours<br>
→ 2/3 of the dose appear in urine as metabolite [within 8 hours after admin.]<br>
→ main metabolic products:<br>
<ul style='padding-left: 30pt'>
<li>3-methoxy-4-hydroxyphenyl acetic acid [HVA-hamovalinic acid]</li>
<li>dihydroxyphenylacetic acid [DOPAC]</li>
</ul>
→ 1-3% of levodopa enter the brain<br>
<ul style='padding-left: 30pt'>
<li>remainder metabolized extracerebrally → by "decarboxylation" to <i>dopamine</i> [which does not penetrate blood-barrier]</li>
</ul>
→ must be give in large doses when used alone.<br>
→ in combination must be given with :<br>
<ul style='padding-left: 30pt'>
<li>dopa decarboxylase inhibitors [that does not penatrate brain]</li>
<li>peripheral metabolism : reduced</li>
<li>plasma level : are higher</li>
<li>plasa half-life : longer     →    dopa is available to entry into the brain</li>
</ul>
→ "<i>Carbidopa" </i>may reduce the daily requirments of levodopa by approx. 75 %<br>
<ul style='padding-left: 30pt'>
<li>reduce peripheral conversion to <i>dopamine.</i></li>
</ul>
</p>

<br>

<h1>2.3 clinical use</h1>

<br>

<p>
→ best results in the first few years of treatment<br>
<ul style='padding-left: 30pt'>
<li>cuz daily dose must be reduced over time to avoid adverse effects.</li>
</ul>
→ overtime becoming less responsive:<br>
<ul style='padding-left: 30pt'>
<li>loss of dopaminergic nigrostriatal nerve terminals</li>
<li>pathologic process of striatal dopamine receptors.</li>
</ul>
→ benifits disminsh after about 3 or 4 years of therapy<br>
→ levodopa does not stop the progression of parkinsonism.<br>
<ul style='padding-left: 30pt'>
<li>but lowers the mortality rate</li>
</ul>
→ used in combination with <i>carbidopa</i><br>
<ul style='padding-left: 30pt'>
<li>e.g.// carbidopa : 25mg  &amp; levodopa : 100mg <a href="file:///C:/" title="/" class="file">/</a> 3 times per day and gradually increased</li>
<li>30-60min before meals</li>
</ul>
→ prefered to keep dosage as low as possible <br>
<ul style='padding-left: 30pt'>
<li>when possible to use a dopamine agonist instead to reduse risk of flacuations.</li>
</ul>
→ controlled -release formulation of carbidopa-levodopa is available<br>
<ul style='padding-left: 30pt'>
<li>(10/100 , 25/100 , 25/250 ) — <i>Parcopa</i> — that disitegrates in the mouth and swallowed → 1 hours before meal</li>
<li>— <i>Stalevo — </i> carbidopa + levodopa + catehol-O-mehtyltranferase inhibitor [<i>entacapone]</i></li>
</ul>
→ finally therapy with intraduodenal infusion appears to be safe<br>
→ ameliorate all the clinical features of parkinson<br>
<ul style='padding-left: 30pt'>
<li>relieving bradikinesia and any disabilities resulting from it.</li>
</ul>
<ul>
<li><img src="./Pharmacology/pasted_image003.png"></li>
</ul>
</p>

<br>

<h1>2.4 Adverse effects</h1>

<p>
A.Gastrointesntinal Effects:<br>
→ without peripheral decarboxylase inhibitors:<br>
<ul style='padding-left: 30pt'>
<li>anorexia</li>
<li>nausea</li>
<li>vomiting in occur about 80</li>
</ul>
→ divided doses with or immediately after meals → increasing the daily dose very slowly <br>
→ antacids taken with 30-60min before levodopa may also be benificial.<br>
<ul style='padding-left: 30pt'>
<li>chemoreceptor trigger zone located in the brainstream</li>
<li>antiemetics such as phenothiazines may be admin.</li>
</ul>
B.Cardiovascular Effects:<br>
→ cardiac arrythmias<br>
<ul style='padding-left: 30pt'>
<li>tachycardia</li>
<li>ventricular extrasystoles</li>
<li>rarely artial fibrilation → [due to increase catecholamine formation peripherilly]</li>
</ul>
→ postular hypotension is common,but often asymptomatic.<br>
C.Behavioral Effects:<br>
→ variety of adverse metnal effect:<br>
<ul style='padding-left: 30pt'>
<li>depression </li>
<li>anxiety </li>
<li>agitation</li>
<li>insomnia</li>
<li>somnolence</li>
<li>confusion </li>
<li>other changes in mood/presonality</li>
</ul>
→ antipsychotics that have low affinity on D2-receptor<br>
<ul style='padding-left: 30pt'>
<li>cloazapine , olanzapine , resperidone used to counteract such behavioral complications.</li>
</ul>
D.Dyskinesias and Response Fluctuations:<br>
→ dyskinesia occur is up to 80%<br>
<ul style='padding-left: 30pt'>
<li>choreoathetosis of the face and distal extremities is the most common presentation.</li>
</ul>
→ fluctuation in clinical response to levodopa occrus with the increasing frequency as treatment continous.<br>
<ul style='padding-left: 30pt'>
<li>relate to the timing of levodopa intake (wearing-off/end-of-dose akinesia)</li>
<li>unrelated to the timing. ( on-off phenomenon)</li>
</ul>
<ul>
<li>off-periods of akinesia alternate over the course of a few hours with on-periods of improved mobility.</li>
</ul>
</p>

<p>
E.Mydriasis<br>
→ actue glaucoma.
</p>

<h1>2.5 Drug Holidays</h1>

<p>
→ discontinuance of the drug for 3-21 days<br>
<ul style='padding-left: 30pt'>
<li>may temprorarily improve responsiveness to levodopa </li>
<li>alleviate some of its adverse effects</li>
<li>little help to in the managment of the on-off  phenomenon.</li>
</ul>
</p>

<h1>2.6Drug Interactions:</h1>

<p>
→pyridoxine (vitamin B6) enchance the extracerebral metabolism of levodopa<br>
<ul style='padding-left: 30pt'>
<li>may prevent therapeutic effect → [unless a peripheral decarboxylase inhibitor is also taken ]</li>
</ul>
→ SHOULD NOT be given to patients<br>
<ul style='padding-left: 30pt'>
<li>taking <i>monoamine oxidase A inhibitors </i>or within 2 weeks of discontinuation. → can lead to hypertensive crises.</li>
</ul>
</p>

<h1>2.7 Contraindication</h1>

<p>
→ SHOULD NOT be given to psychotic patients → exacerbate the mental distribance<br>
→ angle closure/chronic open glaucoma<br>
→ active peptic ulcer  → git bleeding has been reported with levodopa<br>
→ history of melanoma / undiagnosed skin lessions → levo is a prescusor of skin melanin 
</p>

<br>

<h1>3.DOPAMINE RECEPTOR AGONIST</h1>

<p>
→ acting directly on dopamine receptor.<br>
→ they do not require enzymatic conversion to an active metabolite.<br>
→ no potentially toxic metab.<br>
→ do not compete with other substances for active transport into the blood/blood-brain barrier.<br>
→ number of dopamine agonist have antiparkinsonism activity<br>
<ul style='padding-left: 30pt'>
<li>first-line therapy for Parkinson's disease</li>
<li>lower incidence of the response fluctuations + dyskinesia that occur with long-term levodopa therapy.</li>
<li>low dose of carbudipa &amp; levodopa as introduction and a dopamine agonist is then added.</li>
</ul>
→ dose of the dopamine agonist is built up gradually on response and tolerance.<br>
→or on patients with parkinsomism with <br>
<ul style='padding-left: 30pt'>
<li>end-of-dose akinesia</li>
<li>on-off phenomenon</li>
<li>become resistance on treatment with levodopa [dissapointed in patients which failed to repsonsd in levo treatment]</li>
</ul>
</p>

<h1>3.1BROMOCRIPTINE</h1>

<p>
→ d2 agonist;<br>
→ widely to treat Parkinson's disease in the past<br>
<ul style='padding-left: 30pt'>
<li>superseded by the newer dopamine agonist.</li>
</ul>
→ daily dose : 7.5 to 30 mg
</p>

<h1>3.2PERGOLIDE</h1>

<p>
→an other ergot derivative<br>
<ul style='padding-left: 30pt'>
<li>directly stimulates both D1 &amp; D2 receptors.</li>
</ul>
→ widely used for parkinsonism but its not longer available in US<br>
<ul style='padding-left: 30pt'>
<li>associated with the develeopment of valvular heart disease.</li>
</ul>
</p>

<h1>3.3PRAMIPEXOLE</h1>

<p>
→is not ergot derivative<br>
→ but has preferential affinity for the D3 family of receptors<br>
→ effective as monotherapy for mild parkinsonism<br>
→ may ameliorate affective symptoms<br>
→ neuroprotective effect:<br>
<ul style='padding-left: 30pt'>
<li>by it's ability to scavenge hydrogen peroxide and enhance neurotropic activity in mesencephalic dopaminergic cell cutlures.</li>
</ul>
→ rapidly absorbed after oral admin.<br>
→ peak conc. : 2 hours<br>
→ excreted largerly in urine <br>
→ 0.125 mg <a href="file:///C:/" title="/" class="file">/</a> 3 times a day → doubled after 1 week → again after another week<br>
→ further increasement in the daily dose are by 0.75mg at weekly intervals [depending on response/tolerance]<br>
→ extended-release formulation preparation is now available and is taken once a day at a dose equivalent to the total daily dose of standar pramipexole.
</p>

<h1>3.4ROPINIROLE</h1>

<p>
→ not an ergot derivative<br>
→ pure D2-receptor agonist<br>
→ effective monotherapy against mild-disease<br>
<ul style='padding-left: 30pt'>
<li>smoothing response to levodopa</li>
<li>response to fluctuation</li>
</ul>
→ 0.25 mg / 3 times / day → increased by 0.75 mg at weekly intervals [until the 4th week] → by 1.5mg therafter<br>
→ dosage between 2mg and 8 mg times daily is necessary<br>
→ CYP1A2<br>
→ prolonged-release preparation taken once daily is now available. 
</p>

<h1>3.5ROTIGOTINE</h1>

<p>
→ skin patch<br>
→ '07 by FDA for :<br>
<ul style='padding-left: 30pt'>
<li>early parkinson's diseae</li>
</ul>
→ continious dopaminergic stimulation<br>
→ similar adr with the other agonist <br>
<ul style='padding-left: 30pt'>
<li>applicaiton site</li>
</ul>
</p>

<h1>3.6 Adverse Effects of Dopamine Agonist</h1>

<p>
A.GIT EFFECTS<br>
→ anorexia , nausea , vomiting may occur<br>
<ul style='padding-left: 30pt'>
<li>can be minimized with food</li>
</ul>
→ constipation , dyspepsia , symptoms of reflux esophatgitis<br>
→ bleeding from peptic ulceration<br>
B.Cardiovasular Effects<br>
→ postural hypotension (with inhalation therapy)<br>
→ cardiac arrythmias (indication for the discont. of the treatment)<br>
→ cardiac valvulopathy may occur with pergolide.<br>
C.Dyskinesia<br>
→ abnormal movements (similar to levodopa) → reversed by reducing the total dose<br>
D.Mental Distrubances<br>
→ confusion , hallugination , delusion , psyciatric reactions<br>
E.Miscellaneous<br>
→ headache , nasal congestion ,pulmonary infilitrates , fibrosis and other
</p>

<h1>3.7 Contraindication</h1>

<p>
→ patients with history of : <br>
<ul style='padding-left: 30pt'>
<li>psychotic illness </li>
<li>recent myocardial infranctions</li>
<li>active peptic ulceration</li>
</ul>
→ ergot-derived agonists <br>
<ul style='padding-left: 30pt'>
<li>peripheral vascular disease.</li>
</ul>
</p>

<h1>4.MONOAMINE OXIDASE INHIBITORS</h1>

<p>
→monoamine oxidase A metabolizes norepinephrine , serotonin , dopamine <br>
→ monoamine oxidase B metabolizes dopamine selectively 
</p>

<h1>4.1 SELEGILINE (deprenyl)</h1>

<p>
→ selective irrevesrsible inhibitor of monoamine oxidase B at  normal doses<br>
<ul style='padding-left: 30pt'>
<li>at higher doses it inhibits monoamine oxidase A as well </li>
</ul>
→ retards the the breakdown of dopamine.<br>
<ul style='padding-left: 30pt'>
<li>enhance and prolongs the antiparkinsonism effect of levodopa</li>
<li>reduce mild on-off wearing off phenomena.</li>
</ul>
→ adjunctive therapy for patients with a delcining or flucuating response to levodopa<br>
→ daily dosage : 5mg with breakfast &amp; 5 mg with lunch.<br>
→ minor therapeutic effects on parkinsonism when given alone
</p>

<h1>4.2 RASAGILINE</h1>

<p>
→ monoamine oxidase B inhibitor <br>
<ul style='padding-left: 30pt'>
<li>more potent than <i>Selegiline </i>in preventing   MPTP-induced parkinson </li>
<li>is being used for early symptomataic treatment</li>
</ul>
→ standard dosage: 1mg<br>
→ adjunctive therapy at a dosage of 0.5 or 1 mg/d to prolong effects of levo-carbidopa in patients with  advanced disease.<br>
→ should be taken by patients receiving <br>
<ul style='padding-left: 30pt'>
<li>meperidine</li>
<li>tramadol</li>
<li>methadone</li>
<li>propoxyphene</li>
<li>cyclobenzaprine</li>
<li>St.John's wort</li>
<li>antitussive → dextromethorphan should also be avoided by patients taken monoamine oxidase B inhibitors.</li>
</ul>
→ advise patients to avoid all the over-the-counter cold preparations.
</p>

<br>

<h1>5.CATECHOL-0-METHYLTRANFERASE INHIBITORS</h1>

<p>
→ inhibition of dopoa decarboxylase is associated with activation of other pathways of levodopa metabolism<br>
<ul style='padding-left: 30pt'>
<li>catechol-0-methyltranferase(COMT) → increases plasma levels of 3-O-methyldopa</li>
</ul>
→ Selective COMT inhibitors such as <br>
<ul style='padding-left: 30pt'>
<li>"<i>Tolcapone" and " Entacapone " → </i>prolong the action of levodopa by dishmising in peripheral metabolism</li>
<li>levodopa clearance is decreased and so bioavailbility increased.</li>
</ul>
→ may helpful in patients who have developed "response fluctuation"<br>
<ul style='padding-left: 30pt'>
<li>rapidly absorbed</li>
<li>bound to plasma proteins</li>
<li>metabolized before excretion</li>
<li>central + peripheral effects</li>
<li>half-life 2 hours</li>
</ul>
→ "Tolcapone"<br>
<ul style='padding-left: 30pt'>
<li>dosage : 100mg / three times daily </li>
</ul>
→ "Entacapone"<br>
<ul style='padding-left: 30pt'>
<li>dosage 200mg needs to be taken with each dose of levodopa x 5 times/day</li>
</ul>
→ adr:<br>
<ul style='padding-left: 30pt'>
<li>dyskinesia, nausea , confusion</li>
<li>diarhhea , abdominal pain , orthostatic hypotention , sleep distrubances , orange discoloration of the urine.</li>
<li>acute hepatic failure</li>
</ul>
→ Commercial preparation names <i>"Stalevo"</i>.<br>
<ul style='padding-left: 30pt'>
<li>levodopa + carbidopa + entacapone</li>
<li>3 preps. — Stalevo50(50+12.4+200)</li>
</ul>
<div style='padding-left: 90pt'>
   —Stalevo100 (100+25+200)<br>
 — Stalevo 150 (150+37.5+200)
</div>
</p>

<h1>6.APOMORPHINE</h1>

<p>
→ subcutaneous injenction of apomorphine hydrochloride "<i>Apokyn"</i><br>
<ul style='padding-left: 30pt'>
<li>potent dopamine agonist </li>
<li>effective relief (rescue) of off-periods of akinesia</li>
<li>rapidly taken up in the blood → brain.</li>
</ul>
→ nausea/diskinesia/drowsiness/chest pain/sweating/hypotention/bruising at the injenction site.
</p>

<h1>7.AMANTADINE</h1>

<p>
→ anti-viral agent<br>
→ moa in parkinsonism is unclear.<br>
→ but may potentiate dopaminergic function by influencing the synthesis, release , reuptake of dopamine.<br>
→ antagonize effects of adenosine at adenosine A2a receptors<br>
<ul style='padding-left: 30pt'>
<li>which are receptors that may inhibit D2-receptor function</li>
</ul>
→ release of catecholamines from peripheral stores has also been documented.
</p>

<h1>7.1Pharmacokinetics</h1>

<p>
→ peak plasma conc : 1-4hours [oral dose]<br>
→ plasma half-life [2 and 4 hours ]<br>
→ excreted unchanged in the urine.
</p>

<h1>7.2Clinical Use</h1>

<p>
→ less efficacious than levodopa<br>
→ short-lived often dissapeariing after only a few weeks of treatment.<br>
→ standard dosage: 100mg orally 2 or 3 times <a href="file:///C:/" title="/" class="file">/</a> day<br>
→ may also help in reducing iatrogenic dyskinesia.
</p>

<h1>7.3 Adverse Effects:</h1>

<p>
→ central nerbous system effects:<br>
<ul style='padding-left: 30pt'>
<li>which can be reserved by stopping the drug</li>
<li>restlessness</li>
<li>depression </li>
<li>irritability</li>
<li>insomnia</li>
<li>agitation</li>
<li>ecitement</li>
<li>hallucination</li>
<li>confusion</li>
</ul>
→ overdose may produde <br>
<ul style='padding-left: 30pt'>
<li>acute toxic psychosis </li>
<li>convulsions</li>
</ul>
→ peripheral edema<br>
→ headeache , heart failure , postural hypotention , urinary retention , GIT distrubances <br>
→ should be used with caution in patients with a history of seizures / heart failure
</p>

<h1>8.ACETYLCHOLINE-BLOCKING DRUGS</h1>

<p>
→ centrally acting antimuscarinic preparations <br>
<ul style='padding-left: 30pt'>
<li>differ in their potency and their efficasy in different patients.</li>
</ul>
→ may improve<br>
<ul style='padding-left: 30pt'>
<li>tremor and rigidity of parkinsonism</li>
<li>little effect on bradykinesia</li>
<li><img src="./Pharmacology/pasted_image004.png"></li>
</ul>
</p>

<h1>8.1 Clinical Use</h1>

<p>
→ started with a low dose → gradually increased until benifits occurs or adr limit further increments.
</p>

<h1>8.2Adverse Effects</h1>

<p>
→ central nervous system and peripheral effects<br>
<ul style='padding-left: 30pt'>
<li>poorly tolarated by elderly</li>
</ul>
→ withdrawn <br>
<ul style='padding-left: 30pt'>
<li>gradually rather than abruptly to prevent acute excerbation of parkinsonism.</li>
</ul>
</p>

<h1>9.SURGICAL PROCUDURES</h1>

<br>

<h1>10.NEUROPROTECTIVE THERAPY</h1>

<br>

<h1>11.GENE THERAPY</h1>

<br>

<h1>12.GENERAL COMMENTS ON DRUG MANAGMENT OF PATIENTS WITH PARKINSONISM</h1>

<br>


	</div>

	<br />

	<div class='page-footer'>

			<b>Attachments:</b>
			<table>

			<tr><td><a href='./Pharmacology/pasted_image.png'>pasted_image.png</a></td><td>&nbsp;</td><td>15.1kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image001.png'>pasted_image001.png</a></td><td>&nbsp;</td><td>36.3kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image002.png'>pasted_image002.png</a></td><td>&nbsp;</td><td>92.7kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image003.png'>pasted_image003.png</a></td><td>&nbsp;</td><td>92.7kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image004.png'>pasted_image004.png</a></td><td>&nbsp;</td><td>23.4kb</td></tr>

			</table>
	</div>

	

</div>

</body>
</html>
